The recent surge in prescriptions for psychedelic drugs and cannabis in Australia, particularly for treating mental health disorders like depression, has sparked caution among experts. Three new studies have revealed a lack of substantial evidence supporting the efficacy of these substances in treating depression, anxiety, and PTSD. This finding is particularly concerning given the challenges in conducting double-blind clinical trials for these drugs, as participants often know what they are taking, potentially influencing the results.
The first study, published in JAMA Psychiatry, reviewed clinical trials on LSD, psilocybin, peyote, and ayahuasca, concluding that these substances performed no better than traditional antidepressants in treating depression. The second study, also in JAMA Psychiatry, found inconclusive results from a trial on psilocybin, the active ingredient in magic mushrooms. These findings come on the heels of another study in The Lancet, which analyzed 54 clinical trials and found no evidence that cannabis and cannabinoids are effective treatments for depression, anxiety, or PTSD.
Jack Wilson, lead author of the cannabis study and a research fellow at the University of Sydney, emphasizes the importance of evidence-based medicine. He states that the absence of evidence does not justify widespread use, highlighting the need for thorough research and safety assessments.
The difficulty in substituting cannabinoids and psychedelic drugs for placebos in double-blind trials is a significant challenge. Participants often know what they are taking, which can skew results. Sam Moreton, a lecturer in psychology, agrees, noting that the hype around psychedelic therapy has consistently outpaced the evidence.
Susan Rossell, a neuropsychologist, supports the potential of psychedelics in treating depression but emphasizes the need for thorough psychotherapy alongside these therapies. She highlights the importance of qualified psychotherapists in helping patients unpack their experiences and avoid relapses. Rossell also stresses the need for caution and the consideration of other, proven interventions before turning to experimental treatments.
The Therapeutic Goods Administration (TGA) rescheduled psilocybin and MDMA in 2023, making it easier for patients to access these drugs as medicines. However, Dr. Wilson warns against a repeat of the medicinal cannabis journey, which faced similar access challenges until 2021.
In conclusion, while the potential of psychedelics and cannabis in treating mental health disorders is intriguing, the current evidence suggests that these substances are not yet ready for widespread use. Further research, including double-blind trials, is crucial to understanding their true efficacy and safety. The field must address methodological issues and ensure that any potential benefits outweigh the risks.
